


FORM PTO-1390 (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			D/98409 US U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 097787215
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED	
PCT/EP99/07768	11-OCT-1999	16-OCT-1998	
TITLE OF INVENTION High purity composition comprising (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one			
APPLICANT(S) FOR DO/EO/US KIRCHHOLTES, Peter H.G.M., SAS, Gerald A.J.M.T.			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>a. <input type="checkbox"/> is attached hereto.</p> <p>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>			
Items 11 to 20 below concern document(s) or information included:			
<p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input type="checkbox"/> Other items or information:</p>			
EXPRESS MAIL NO. EL400659425US			

U.S. PATENT AND TRADEOFFICE 09/7787215	INTERNATIONAL APPLICATION NO PCT/EP99/07768	ATTORNEY'S DOCKET NUMBER D/98409 US																																																												
21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =		CALCULATIONS PTO USE ONLY <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">\$860.00</td> <td style="width: 40%;"></td> </tr> <tr> <td>\$</td> <td></td> </tr> </table>	\$860.00		\$																																																									
\$860.00																																																														
\$																																																														
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30 <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%;">CLAIMS</th> <th style="width: 20%;">NUMBER FILED</th> <th style="width: 20%;">NUMBER EXTRA</th> <th style="width: 20%;">RATE</th> <th style="width: 20%;">\$</th> </tr> <tr> <td>Total claims</td> <td>17 - 20 =</td> <td></td> <td>x \$18.00</td> <td>\$</td> </tr> <tr> <td>Independent claims</td> <td>2 - 3 =</td> <td></td> <td>x \$80.00</td> <td>\$</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>\$</td> </tr> <tr> <td colspan="4"></td> <td>+ \$270.00</td> </tr> <tr> <td colspan="4">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$ 860.00</td> </tr> </table>		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	Total claims	17 - 20 =		x \$18.00	\$	Independent claims	2 - 3 =		x \$80.00	\$	MULTIPLE DEPENDENT CLAIM(S) (if applicable)				\$					+ \$270.00	TOTAL OF ABOVE CALCULATIONS =				\$ 860.00	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;"><input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.</td> <td style="width: 40%;">+</td> </tr> <tr> <td colspan="2">SUBTOTAL =</td> </tr> <tr> <td colspan="2">\$</td> </tr> <tr> <td colspan="2">Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</td> </tr> <tr> <td colspan="2">\$</td> </tr> <tr> <td colspan="2">TOTAL NATIONAL FEE =</td> </tr> <tr> <td colspan="2">\$ 860.00</td> </tr> <tr> <td colspan="2">Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +</td> </tr> <tr> <td colspan="2">\$</td> </tr> <tr> <td colspan="2">TOTAL FEES ENCLOSED =</td> </tr> <tr> <td colspan="2">\$ 860.00</td> </tr> <tr> <td colspan="2">Amount to be refunded:</td> </tr> <tr> <td colspan="2">\$</td> </tr> <tr> <td colspan="2">charged:</td> </tr> <tr> <td colspan="2">\$ 860.00</td> </tr> </table>	<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.	+	SUBTOTAL =		\$		Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$		TOTAL NATIONAL FEE =		\$ 860.00		Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +		\$		TOTAL FEES ENCLOSED =		\$ 860.00		Amount to be refunded:		\$		charged:		\$ 860.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$																																																										
Total claims	17 - 20 =		x \$18.00	\$																																																										
Independent claims	2 - 3 =		x \$80.00	\$																																																										
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				\$																																																										
				+ \$270.00																																																										
TOTAL OF ABOVE CALCULATIONS =				\$ 860.00																																																										
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.	+																																																													
SUBTOTAL =																																																														
\$																																																														
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).																																																														
\$																																																														
TOTAL NATIONAL FEE =																																																														
\$ 860.00																																																														
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +																																																														
\$																																																														
TOTAL FEES ENCLOSED =																																																														
\$ 860.00																																																														
Amount to be refunded:																																																														
\$																																																														
charged:																																																														
\$ 860.00																																																														
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>02-2334</u> in the amount of \$ <u>860.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-2334</u> A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.																																																														
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status. SEND ALL CORRESPONDENCE TO: MICHAEL G. SULLIVAN AKZO NOBEL PATENT DEPARTMENT 1300 PICCARD DRIVE SUITE 206 ROCKVILLE, MD 20850 PHONE: 301-948-71400																																																														
SIGNATURE  MICHAEL G. SULLIVAN NAME		35,377 REGISTRATION NUMBER																																																												

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

KIRCHHOLTES, Peter H.G.M., SAS, Gerard A.J.M.T.

Serial No.: To be assigned Group Art Unit: To be assigned

Filed: Concurrently herewith Examiner: To be assigned

For: HIGH PURITY COMPOSITION COMPRISING (7α , 17α)-17-
HYDROXY-7-METHYL-19-NOR-17-PREGN-5(10)-EN-20-YN-3-ONE

Corresponding to: PCT/EP99/07768, filed October 11, 1999.

PRELIMINARY AMENDMENT

March 15, 2001

Honorable Assistant Commissioner
Patents & Trademarks
Washington, D.C. 20231

Sir:

Prior to examination, in order to present the claims for initial consideration using terminology and formats conventionally accepted by the U.S. Patent and Trademark Office, please amend claims 1-4, 6, 7 and 9-14, and substitute them for pending claims 1-4, 6, 7 and 9-14, cancel claim 8 and add claims 15-18, as follows:

IN THE CLAIMS:

1. Highly pure (7α , 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one, comprising (7α , 17α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one in an amount less than 0.5% by weight.

09787215 051701

2. The highly pure (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one according to claim 1, wherein the amount of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 0.25% or less.
3. The highly pure (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one according to claim 1, wherein the amount of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 0.1% or less.
4. A process for preparing the highly pure (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one of claim 1, comprising aging crystals of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one in the presence of water for at least 24 hours.
6. The process according to claim 4, wherein the crystals are formed in the last step of synthesis comprising the steps of
 - a. reacting (7 α ,17 α)-3,3-dimethoxy-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one in an organic solvent with a weak acidic aqueous solution,
 - b. pouring out the solution in water which is slightly alkaline, and
 - c. washing the crystals with water which is slightly alkaline.
7. A pharmaceutical dosage unit comprising a pharmaceutically suitable solid carrier and the highly pure (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one of claim 1.

Please cancel claim 8 without prejudice or disclaimer of the subject thereof.

9. A dosage unit comprising a pharmaceutically suitable solid carrier and (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one in an amount of less than 2.50 mg, which is less than 5% by weight of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one.
10. The dosage unit according to claim 9, wherein (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one is present in an amount of 1.25 mg or less.
11. The dosage unit according to claim 9, wherein (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one is present in an amount of 0.625 mg or less.
12. The dosage unit according to claim 9, wherein the shelf life is at least 1.5 years.
13. The dosage unit according to claim 9, wherein at a shelf life period of 6 months the amount of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 3% or less by weight of the (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one.
14. The dosage unit according to claim 13 wherein the shelf life period is 1 year.

Please add the following new claims:


- 15. The dosage unit according to claim 12, wherein the shelf life is at least 2 years. --
- 16. The dosage unit of claim 13, wherein the amount of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 2% or less. --
- 17. The dosage unit of claim 14, wherein the shelf life period is at least 1½ years. --
- 18. The dosage unit of claim 14, wherein the shelf life period is at least 2 years. --

REMARKS

Claims 1-4, 6, 7 and 9-14 were amended, claim 8 cancelled and claims 15-18 added in order to adopt conventional U.S. Patent and Trademark Office terminology and formats, and to eliminate multiple dependencies. These amendments were not made for purposes of patentability under 35 USC §§101, 102, 103 or 112.

It is believed that claims 1-7 and 9-18 recite a patentable improvement in the art. Favorable action is solicited.

Respectfully submitted,



Michael G. Sullivan
Attorney for Applicants
Registration No. 35,377


Attorney Docket No. D/98409 US
Akzo Nobel Patent Dept.
1300 Piccard Drive, Suite 206
Rockville, Maryland 20850
Tel: (301) 948-7400
Fax: (301) 948-9751

MGS:lcf
31KIRCHHOLTES PRE-AMENDMENT

High purity composition comprising (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one

5 The invention relates to a high purity composition comprising (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one, a method for the preparation of this compound for use in the pharmaceutical composition as well as a pharmaceutical composition prepared by admixing a pharmaceutically suitable carrier and the high purity composition.

10 The compound (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one (Tibolone) having the structural formula 1:



Formula 1

15 is known, for example from US 3,340,279 and US Patent 4,701,450. The method described in these patents leads to a compound having combined oestrogenic, progestagenic and androgenic characteristics. This compound is used in medicaments having gonadomimetic, ovulation-inhibiting or immuno-modulating action.

20 Compositions comprising Tibolone and a pharmaceutically acceptable solid carrier have been described in EP 389 035, which disclosure is incorporated herein by reference. Tablets are available on the market under the name of Livial®.

25 The known tablets can be stable stored very well for, typically, 2 years at ambient temperature. A sufficiently humid atmosphere (e.g. 50 - 70 % relative humidity) makes for a better storage stability than a relatively dry atmosphere (e.g. 45% relative humidity or below that).

A problem in the preparation of pharmaceutical dosage units is that during the preparation the relative amount of impurities may increase. In particular, the amount of one of the impurities which is already present in the bulk preparation i.e. (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one (Org OM38) tends to increase during the process of making pharmaceutical dosage units. It is furthermore known that the amounts of Org OM38 in compositions comprising Tibolone increase upon storage.

The end of shelf life specification with respect to the amount of Org OM38 formed during storage is 5%. A minimum acceptable shelf life period for these dosage units is 1 year. It is an object of the present invention to improve upon the storage stability i.e. to enhance the shelf-life of the dosage units.

The customary amount of Tibolone in the known dosage unit is 2.5 mg in tablets or capsules of 100 mg, i.e. 2.5%. For the sake of providing therapies better tailored to the individual woman's needs, it is desired to provide dosage units having a lower amount.

However, adaptation of a known formulation by simply including a lower amount of Tibolone further decreases the stability of the dosage unit substantially. E.g., if a 2.5 mg Tibolone dosage unit has a shelf-life of, e.g., 2-3 years at room temperature, the same unit upon lowering the amount of Tibolone to e.g. 0.3 mg can only be kept at 4°C for a period of 6-12 months. Such a lower stability is unacceptable in daily practice. It is a further object of the invention to provide dosage forms having a lower content of Tibolone (which are more prone to stability problems than regular dosage forms) and that can be suitably kept for a prolonged period of time.

One of the possibilities to keep the amount of Org OM-38 below a desired level also after a prolonged storage time is to limit the amount initially present in the bulk preparation. Thus, there is a need to synthesize high purity Tibolone batches with a low contamination content of Org OM-38. It is an object of the present invention to provide for such high purity batches of Tibolone.

During the last step of the synthesis of Tibolone a solution of (7 α ,17 α)-3,3-dimethoxy-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one in a mixture of pyridine and ethanol is mixed with a solution of oxalic acid in water and the mixture is stirred for 3 hours at approximately 30 °C. The solution is then poured out in a mixture of pyridine and water and the resulting suspension is filtered. The crystals are washed with a mixture of water and pyridine and subsequently, the crystals are dried under

vacuum at 40 °C to give (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (see also van Vliet et al (1986), Recl.Trav.Chim.Pays-Bas 105, 111-115).

As this compound has a lower stability than the corresponding (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-pregn-4-en-20-yn-3-one there is always formed a small percentage of the latter compound via acid catalyzed isomerisation. Furthermore, this isomerisation takes place at higher temperature and upon long term storage of the crystals

Unexpectedly, it now has been found that the rate of formation of Org OM38 during drying and storage in a specific batch can be decreased if crystals of Tibolone are washed with water and are allowed to age for at least 24 hours in the presence of water. Thus, the Tibolone is left for at least 24 hours under wet conditions. Preferentially the crystals are left under these conditions for a period of at least 3 days. There is no limit to a maximum period but a period of 3-6 days is best suited. The aging temperature preferentially is room temperature.

Thus according to the procedure of the present invention highly pure Tibolone with a low Org OM38 impurity is obtained by including a delay of several days before drying. The procedure reliably results in batches of Tibolone having a low Org OM38 content. A further advantage is that these batches have an excellent stability. Furthermore, these batches do not form additional amounts of the latter compound upon heating or long term storage.

The crystal formation procedure of the present invention can perfectly well be combined with the last step of the Tibolone synthesis wherein (7 α ,17 α)-3,3-dimethoxy-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one in a mixture of pyridine and ethanol is mixed with a solution of oxalic acid in water. In general, this reaction proceeds under mild acidic conditions in the presence of an organic solvent and water within a pH range of 5-3, preferentially 3.5-4.5. The acid preferentially is a weak organic acid having a pKa value in the range 1-5 such as citric acid, malonic acid, oxalic acid, dichloroacetic acid and acetic acid, optionally buffered with a base such as pyridine. As organic solvent e.g. ethanol, methanol, acetone, 2-propanol or tetrahydrofuran can be used. The solution is then poured out in water, which is made slightly alkaline by addition e.g. of a low amount of pyridine. After filtering the suspension the crystals are washed with a mixture of water made slightly alkaline by e.g. pyridine. Before drying the crystals are left wet for at least 24 hours.

Inclusion of the crystal aging step according to the invention results in bulk Tibolone batches with a low Org OM38 content. Routinely, batches are obtained with an Org OM38 content of less than 0.5%. Often even batches with less than 0.25% or even 0.1% of Org OM38 are obtained. Thus high purity compositions with Tibolone having less than 0.5% of Org OM38, preferably 0.25%, more preferably 0.10% of Org OM38 form part of the present invention. The amount of Org OM38 is calculated as the percentage (w/w) of the total amount of the bulk substance including some minor impurities. The amount of Tibolone usually is more than 98%.

The batches of these high purity Tibolone compositions with their low initial Org OM38 content are perfectly well suited to be used as a source for the preparations of pharmaceutical formulations. This guarantees a formulation with a low initial Org OM38 content and improves therefore its storage properties. Pharmaceutical preparations prepared with high purity Tibolone usually result in preparations with less than 1% of Org OM38, often even less than 0.7% of Org OM38 and these preparations are less prone to increase in Org OM38 content during storage.

As indicated before the amount of Org OM38 in a dosage form also depends upon the concentration of the active substance, the amount of impurity being higher as the amount of Tibolone in the dosage unit decreases. Therefore, using high purity Tibolone as the active substance, dosage units can now be prepared with a lower amount of Tibolone and still having an acceptable shelf life. Thus, the invention also relates to pharmaceutical dosage units, which can be prepared by admixture of a pharmaceutically suitable solid carrier and the high purity composition of the present invention.

A typical known formulation for Tibolone is a 100 mg dosage unit having 2.5 mg of Tibolone contained therein, a relatively small amount (e.g. approximately 1 % by weight) of pharmaceutically acceptable auxiliaries, and a carrier making up the body of the tablet. The carrier typically is composed of 10 % by weight of starch, e.g. potato starch, and 90 % by weight of lactose.

Due to the excellent stability properties of dosage units with a lower amount of active substance than the present commercially available tablets of 2.5 mg active substance, the present invention now makes it also possible to provide for stable dosage units comprising Tibolone in an amount of less than 2.50 mg, preferably 1.25 mg or less, more preferably 0.625 mg or less. At a shelf life of 1.5 years, preferably 2 years these dosage units still comprise less than 5% of OM38 (relative to the amount of Tibolone).

It is another aspect of the present invention to provide dosage units comprising Tibolone in amounts of less than 2.50 mg, preferably 1.25 mg or less, more preferably

0.625 mg or less and comprising at a shelf life of 6 months less than 3 %, preferably 2 % of OM38. The shelf life preferably is extended up to 1 year, preferably 1.5 year, more preferably 2 years.

As used herein shelf life means storage during a specified period under temperature conditions varying from 2-25 °C. Dosage units can be packed e.g. in push-through packs (PTP, blister) and are preferably stored in dark (e.g. enclosed in carton). Alternatively they might also be stored in bottles e.g. high-density polyethylene bottles.

The pharmaceutical dosage units of the present invention will generally take the form of tablets or capsules, but other solid or dry pharmaceutical preparations are included.

Methods for making such dosage units are well known. For example in the standard English language text Gennaro et al., Remington's Pharmaceutical Sciences, (18th ed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical Preparations and Their Manufacture), methods of making tablets, capsules and pills and their respective components are described.

Tablets and capsules are prepared of granulates using dry or wet granulation techniques as disclosed in The Theory and Practice of Industrial Pharmacy (Third edition) L. Lachman, H.A. Lieberman and J. L. Kanig (1986) p 1 -99 and 293 - 345.

The aim of granulation is to improve the flowability and compressibility of the powder mixture. Wet granulation forms the granules by binding the powders (a mixture of a diluent and disintegrant) together with an adhesive. The wet granulation technique employs a solution, suspension or slurry containing a binder, which is usually added to the powder mixture; however the binder may be incorporated dry to the powder mix and the liquid may be added by itself. The wet granulation process is performed in mixers/kneaders or fluid bed systems.

Usually an amount of water is incorporated in the basic granulate ranging from 5.5 - 7 %. Preferably the amount of water incorporated is at least 6%.

After granulation the mass is dried to the desired water content using fluid bed dryers, tray dryers, vacuum dryers or other suitable dryers.

To attain a good distribution of the active (Tiboione) over the total mass, the active is premixed with a part of the granulate, sieved using an oscillating sieve, a high speed sieve or other suitable sieving equipment. Next this mixture is mixed with the remaining part of the granulate and a lubricant. This mixture is compressed to tablets, or filled into capsules.

The following examples are illustrative for the invention and should in no way be interpreted as limiting the scope of the invention.

5

Examples

Example 1

10 A solution of (7 α ,17 α)-3,3-dimethoxy-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (15 kg) in a mixture of pyridine (630 ml) and ethanol (315 litres) was mixed with a solution of oxalic acid (750 gr) in water (90 litres) and the mixture was stirred for 2 hours at approximately 30 °C. The solution was poured out in a mixture of pyridine (1350 ml) and water (300 litres) and the resulting suspension was filtered. The crystals were washed with a mixture of water and pyridine and dried under vacuum at 40 °C to give (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one containing 15 0.6% of the corresponding (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-4-en-20-yn-3-one as indicated by HPLC analysis; a stress test at 45 °C (duration 1 month) indicated a 0.4% increase of the latter compound.

20

Example 2

A solution of (7 α ,17 α)-3,3-dimethoxy-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (15 kg) in a mixture of pyridine (630 ml) and ethanol (315 litres) was mixed with a solution of oxalic acid (375 gr) in water (90 litres) and the mixture was stirred for 3 hours at approximately 30 °C. The solution was poured out in a mixture of 25 pyridine (1350 ml) and water (300 litres) and the resulting suspension is filtered. The crystals are washed with a mixture of water and pyridine and allowed to age for 3-6 days at room temperature. Subsequently, the crystals were dried under vacuum at 40 °C to give (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one containing \leq 0.1% of the corresponding (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-4-en-20-yn-3-one as indicated by HPLC analysis; a stress test at 45 °C (duration 1 week) indicated a < 30 0.1% increase of the latter compound.

Example 3

The preparation as described in example 2 was repeated. (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one was obtained which contained 0.2 % of the corresponding (7 α ,17 α)-17-hydroxy-7-methyl-19-norpregn-4-en-20-yn-3-one as indicated by HPLC analysis; a stress test at 45 °C (duration 1 week) indicated a 0.1% increase of the latter compound.

Example 4

A basic granulate was prepared by granulation of a mixture of lactose (diluent), potato starch (disintegrant) and potato starch mucilage (binder) in a fluid bed granulator. The water content of the granulate varied within 5.5% - 6.5%. After granulation, the basic granulate was passed through a conical high speed sieve. Part of the granulate (10 % w/w) was mixed with Tibolone and ascorbyl palmitate using a tumble blender and then passed through a conical high speed sieve.

The Tibolone premix and the remainder of the basic granulate were mixed in a ribbon blender. Magnesium stearate was added and mixed. The final granulate was compressed into round tablets.

The stability of the active compound (Tibolone) in tablets was determined.

Table 1: Content of decomposition product (Org OM38) in percentage of the declared amount of Tibolone per tablet, in tablets containing a various amount of Tibolone, after storage at 25°C and 60% relative humidity.

Storage time (months)	Concentration of Tibolone per tablet			
	0.46	0.96	1.92	2.5
	Amount of Org OM38 formed during storage (in percentage of the declared amount of tibolone)			
0	1.2	0.8	0.5	0.4
6	6.5	3.5	1.8	1.6
12	9.5	5.1	2.7	2.2
18	12.2	6.1	3.3	2.7

Example 5

Tablets of 1.25 mg of Tibolone have been prepared as described in example 4. The tablets were stored at 25°C and 60% relative humidity and the decomposition product (Org OM38) was measured.

Table 2: Content of decomposition product (Org OM38) in percentage of the declared amount of Tibolone per tablet. Stability of three development tablet batches (1.25 mg of Tibolone per 65 mg) was assessed (storage at 25°C and 60% relative humidity).

Storage time (months)	Batch no		
	049514001	049515001	049516001
	Amount of Org OM38 formed during storage (in percentage of the declared amount of Tibolone)		
0	0.7	1.0	1.3
6	2.3	2.6	2.9
12	3.5	3.7	3.8
18	4.3	4.2	4.3
24	5.1	4.9	4.9

It can be concluded that the shelf life of tablets containing 1.25 mg of Tibolone per tablet of 65 mg is borderline .

Example 6

Tibolone as prepared as in example 2 was used as the active compound to prepare tablets as described in example 4. The amount of Org OM38 formed in several batches during storage was determined.

Table 3: The stability of six tablet batches (1.25 mg of Tibolone per 65 mg) was assessed (storage at 25°C and 60% relative humidity). The amount of water incorporated in the basic granulate was varied from 6.0% to 6.5%.

Storage time (months)	Batch no					
	TD96.1128	TD96.1132	TD96.1133	162454001	162455001	162456001
	Amount of Org OM38 formed during storage (in percentage of the declared amount of Tibolone)					
0	0.7	0.5	0.5	0.9	0.8	0.9
6	1.3	1.1	1.1	1.8	1.7	1.8
12	1.8	1.5	1.6			
18	2.0	1.5	1.7			
Water content of the basic granulate	6.5	6.5	6.5	6.3	6.1	6.1

09/07/2015 05:17:01

Claims

1. A high purity composition comprising (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one, characterized in that the said composition comprises
5 (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one in an amount less than 0.5%.
2. The composition according to claim 1 characterized in that the amount of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 0.25% or less.
3. The composition according to claim 1 characterized in that the amount of (7 α ,17 α)-
10 17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 0.1% or less.
4. A process for preparing the high purity compositions of claims 1-3 characterized in that crystals of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one are allowed to age in the presence of water for at least 24 hours.
5. The process according to claim 4 wherein the aging lasts 3-6 days.
- 15 6. The process according to claims 4 or 5 characterized in that the crystals are formed in the last step of the Tibolone synthesis comprising the steps of
 - a. reacting (7 α ,17 α)-3,3-dimethoxy-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one in an organic solvent with a weak acidic aqueous solution
 - b. pouring out the solution in water which is made slightly alkaline
 - 20 c. washing the crystals with water which is made slightly alkaline.
7. A pharmaceutical dosage unit obtainable by admixture of a pharmaceutically suitable solid carrier and the composition according to any one of the claims 1-3.
8. A pharmaceutical dosage unit obtainable by admixture of a pharmaceutically suitable solid carrier and the composition obtainable by the process of claims 4-6.
- 25 9. A dosage unit comprising a pharmaceutically suitable solid carrier and (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one in an amount of less than 2.50 mg and having a shelf life specification comprising less than 5% of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one.
10. The dosage unit according to claim 9 characterized in that (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one is present in an amount of 1.25 mg
30 or less.

11. The dosage unit according to claim 9 characterized in that (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one is present in an amount of 0.625 mg or less.
12. The dosage unit according to claims 9-11 wherein the shelf life is 1.5 , more
5 preferably 2 years.
13. The dosage unit according to claim 9-11 wherein at a shelf life period of 6 months the amount of (7 α ,17 α)-17-hydroxy-7-methyl-19-nor-17-pregn-4-en-20-yn-3-one is 3 % or less, more preferably 2% or less.
14. The dosage unit according to claim 13 wherein the shelf life period is 1. preferably
10 1 ½ year, more preferably 2 years.

09787215-051701

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original first and joint inventor (if plural names are listed below) of the subject matter for which a patent is sought on the invention entitled:

*“High purity composition comprising
(7a,17a)-17-hydroxy-7-methyl-19-nor-17-pregn-5-(10)-en-20-yn-3-one”*

the specification of which

[CHECK ONE]

☐ is attached hereto

☐ was filed on _____ as Application Serial No.

_____ and was amended on _____
[if applicable]

☒ [X] as filed under the Patent Cooperation Treaty on **11/10/99**
Serial **EP99/07768** , The United States of America being designated.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined Title 37, Code of Federal Regulations Section 1.56(a)

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign applications(s) for patent or inventor's certificate having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s)

98203460.5

EP

16/ 10 / 1998

Priority claimed

☒ Yes ☐ No

Number

Country

Day/Month/Year filed

Number

Country

Day/Month/Year filed

☐ Yes ☐ No

Number

Country

Day/Month/Year filed

☐ Yes ☐ No

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the patent and Trademark

Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application.

(U.S. Serial No.) (Filing date) (Status-patented, pending, abandoned)

(U.S. Serial No.) (Filing date) (Status-patented, pending, abandoned)

And I hereby appoint as principal attorney, William M. Blackstone, Registration No. 29,772, and Michael G. Sullivan, Registration No. 35,377.

Please address all communications to:

William M. Blackstone

AKZO NOBEL

1300 Piccard Drive #206

Rockville, MD 20850-4373

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Kirchholtes, P.H.G.M.

Peter Huub Gerard Maria

Inventor's signature [Signature]

Date

Citizenship Dutch

22-03-2001

Residence and P.O. Address Gewandeweg 58

5345 HN Oss

The Netherlands

Full name of second joint inventor Sas, G.A.J.M.Th.

Gerard Arnold Jozef Maria Theresia

Inventor's signature [Signature]

Date

Citizenship Dutch

22-03-2001

Residence and P.O. Address Vlas en Graan 79

5461 KL Veghel

The Netherlands

Full name of third joint inventor _____

Inventor's signature _____

Date

Citizenship _____

Residence and P.O. Address _____